Denmark· DK-28105926117
Blitzima
A rituximab product containing rituximab, registered in Denmark by Celltrion Healthcare Hungary Kft. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Rituximab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FA01 (rituximab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Rituximab · ATC L01FA01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rituximab costs, country by country.
Normalised to the WHO defined daily dose (67 mg), the median price runs from $3.15 in Finland to $96.14 in Switzerland — a ×31 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rituximab · price per daily dose (67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$96.14
- FI Finland$3.15
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- RITUXIMAB
- Manufacturer
- Celltrion Healthcare Hungary Kft
- Country
- Denmark (DK)
- ATC code
- L01FA01
- ATC class
- Rituximab
- Defined daily dose
- 67 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105926117
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for rituximab.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rituximab · interactions on record
81 records
- 32 severe
- 42 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FA01
Rituximab, as other registers publish it.
- DenmarkBlitzimaCelltrion Healthcare Hungary Kft
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- PolandBlitzimaCelltrion Healthcare Hungary Kft.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/192bf173-873f-475c-81ab-326efb4a7830 GET /v1/drugs/192bf173-873f-475c-81ab-326efb4a7830?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "500 mg",
"auth_role": "MOD",
"dk_drugid": "28105926117",
"substance": "RITUXIMAB",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "42933"
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.